Our Parkinson's Place: 5 Key Findings Presented at 2018 Parkinson Disease Conference

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Wednesday, August 29, 2018

5 Key Findings Presented at 2018 Parkinson Disease Conference

Tom Greenhalgh, Medical Marketing Writer August 29, 2018

At the World Congress on Parkinson's Disease (PD) and Related Disorders, speakers from across the globe shared findings from recent trials and clinical studies.

The International Association of Parkinsonism and Related Disorders (IAPRD) recently held its annual World Congress on Parkinson's Disease (PD) and Related Disorders August 19-22 in Lyon, France. Speakers from around the world gathered to share the latest therapeutic updates in PD and other movement disorders. Here are 5 key findings presented at the conference:

1. APL-130277 may provide clinically meaningful benefits for patients with PD experiencing off episodes. A 12-week, double-blind trial was conducted in patients with PD experiencing off episodes to evaluate the efficacy of APL-130277. APL-130277 is a new formulation of apomorphine designed to treat motor fluctuations that occur during off episodes between regular doses of PD therapy. Clinical data showed that APL-130277 has superior efficacy vs placebo for the treatment of off episodes associated with PD.

Study: Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: results from the phase 3 double-blind, placebo-controlled trial

2. Nilotinib may be a new treatment option for PD. Data from a phase 2 clinical trial suggests nilotinib may increase dopamine levels and metabolism in patients with PD. Nilotinib, which is an approved treatment for certain types of leukemia, blocks the activity of a protein (Bcr-Abl) known to promote cancer development. Findings from this study suggest patients with PD may experience long-term benefits from nilotinib treatment.

Study: Nilotinib increases dopamine metabolism and reduces oligomeric: total alpha-synuclein ratio in Parkinson's disease

3. Opicapone may reduce off time in patients with PD. A phase 3 clinical study of once-daily treatment with opicapone demonstrated reduction in off periods in patients with PD who are taking levodopa. Patients who were administered 50-mg doses showed especially favorable profiles vs patients who received placebo. Opicapone is intended for adults with PD as a once-daily add-on therapy to levodopa.

Study: Efficacy of opicapone in Parkinson's disease patients with motor fluctuations: Results from the BIPARK I study

4. Once-daily valbenazine may improve tardive dyskinesia in the long term. A study was conducted to explore the long-term effects of once-daily valbenazine on tardive dyskinesia. Significant improvements were noted in adults, and no safety signals were detected.

Study: Effects of long-term valbenazine on tardive dyskinesia and patient-reported outcomes: results from the KINECT 4 study

5. Pain may be an early indicator of PD. Researchers found indirect evidence that pain may be an important clinical marker of PD in the absence of motor impairment. They noted, however, that longitudinal studies are needed to better evaluate the predictive value of pain for the development of PD.

Study: Pain: a marker of prodromal Parkinson's disease?

https://www.neurologyadvisor.com/movement-disorders-advisor/2018-parkinson-disease-conference/article/791877/